



Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting

April 22, 2024

Presentation to highlight baseline characteristics of Spruce's CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 22, 2024-- [Spruce Biosciences, Inc.](#) (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the [Pediatric Endocrine Society \(PES\) 2024 Annual Meeting](#) taking place May 2-5, 2024, in Chicago, IL.

In the poster presentation, Paul Thornton, M.B.B.S., will highlight baseline characteristics from Spruce's CAHmelia program evaluating tildacerfont in adult congenital adrenal hyperplasia (CAH), as an illustration of outcomes of current pediatric CAH disease management.

PES 2024 Presentation Details:

Title: Baseline Characteristics of Two Randomized, Placebo-controlled Trials with Tildacerfont in Adults (CAHmelia Studies) Highlight Unmet Medical Need in Pediatric Congenital Adrenal Hyperplasia

Abstract Number: 6898

Poster Session: 2

Session Date & Time: Friday, May 3, 2024: 12:15 – 1:45 p.m. CT

Presenter: Paul Thornton, M.B.B.S., Principal Investigator and Medical Director of the Endocrine and Diabetes Program at a CAH Center of Excellence

The poster will be available on the [company's website](#), beginning May 3, 2024 at 12:15 p.m. CT. Access more information about PES 2024 [here](#).

About Spruce Biosciences

Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal, once-daily therapy for patients suffering from classic congenital adrenal hyperplasia (CAH) and other endocrine disorders. To learn more, visit www.sprucebio.com and follow us on [X](#), [LinkedIn](#), [Facebook](#), and [YouTube](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240422001816/en/): <https://www.businesswire.com/news/home/20240422001816/en/>

Media Contact

Katie Beach Oltsik

Inizio Evoke Comms

(937) 232-4889

Katherine.Beach@inizioevoke.com

media@sprucebio.com

Investors

Samir Gharib

President and CFO

Spruce Biosciences, Inc.

investors@sprucebio.com

Source: Spruce Biosciences, Inc.